Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
August 16, 2011
MIAMIThe U.S. District Court, Southern Florida, issued a final judgment in favor of Starmark Laboratories in its patent infringement case against Creative Compounds LLC. According to the judgment issued by the court, Creative is hereby enjoined from manufacturing, marketing, selling and importing dicreatine malate, any products containing dicreatine malate or any other product that infringes upon Starmarks U.S. patent (#7,109,373). The judgment also requires Creative to pay a $112,500 penalty plus judgment interest.
This follows a similar judgment earlier this year against Creative Compounds for infringement of trademarks owned by Sabinsa Corp. That case that went to the Supreme Court, which refused to hear appeal on a lower courts decision that Creatives Forsthin created market confusion with Sabinsas ForsLean®both products are based on Coleus forskohlii. The lower court had deemed ForsLean commercially strong and said the law, thus favors Sabinsa in this case.
You May Also Like
Dr. Mercola allegedly plans to introduce psychic advisor to followersMar 1, 2024
The Vitamin Shoppe general counsel criticizes NY age-restriction lawMar 1, 2024
Is kratom a safe life-giver or a dangerous life-taker?Mar 1, 2024
Patents can offer supplement brands competitive advantageMar 1, 2024